Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices

Wednesday's analyst upgrades and downgrades Add to ...

Subscribers Only

Inside the Market’s roundup of some of today’s key analyst actions

RBC Dominion Securities analyst Douglas Miehm believes Valeant Pharmaceuticals International Inc.’s (VRX-N, VRX-T) management may lower guidance “for some time” due largely to higher-than-expected expenses as it attempts to revive its business.

Report Typo/Error

Follow on Twitter: @daveleeder

 

More Related to this Story

Topics

Next story

loading

In the know

The Globe Recommends

loading

Most popular videos »

Highlights

More from The Globe and Mail

Most popular